A first-in-human dose escalation and expansion study to evaluate the safety, and tolerability of AZD8421 alone or in combination in participants with selected advanced or metastatic solid tumors

Trial Identifier: D8470C00001
Sponsor: AstraZeneca
NCTID:: NCT06188520
Start Date: December 2023
Primary Completion Date: June 2025
Study Completion Date: June 2025
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU East Melbourne, AU, 3002
ES Barcelona, ES, 8035
ES Pamplona, ES, 31005
GB Cambridge, GB, CB2 0XY
GB Leeds, GB, LS9 7TF
GB London, GB, EC1A 7BE
GB Manchester, GB, M20 4BX
KR Seoul, KR, 03722
KR Seoul, KR, 06351
US, MO Saint Louis, MO, US, 63141
US, RI Providence, RI, US, 02903
US, TN Nashville, TN, US, 37201
US, TX Houston, TX, US, 77030